The rapid expansion of this drug class since 2005 reflects growing recognition that managing blood sugar and body weight requires sophisticated, multi system approaches rather than single organ treatments
Eli Lilly, the maker of Zepbound and Mounjaro, had pushed back against the OFA's assertion that shortages of tirzepatide were still in place, and has also claimed that versions of the drug made by compounded pharmacies are often "untested, unapproved knockoffs," according to NBC News
It also examined quality of life outcomes
The Japanese intranasal GLP-1 trial specifically noted low adverse events, especially nausea and vomiting, compared to injectable exenatide and liraglutide
The honest summary is that the biology is sound and the early signals are encouraging, but the proof most of us would want, consistent results in robust human trials, is still being built